Alavian Seyed-Moayed, Mansouri Siavash, Abouzari Mehdi, Assari Shervin, Bonab Mirmohsen Sharifi, Miri Seyed-Mohammad
Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Eur J Gastroenterol Hepatol. 2008 Feb;20(2):131-4. doi: 10.1097/MEG.0b013e3282f1cc28.
This study was conducted to evaluate the 16-year efficacy of hepatitis B virus (HBV) vaccine in healthcare workers of Oil Company Hospital, Tehran, Iran.
Two hundred healthcare workers were enrolled in the study in 1989. All HBV markers were tested and those with positive HBV markers, positive antihepatitis C virus or anti-HIV were excluded from the study. The remaining participants received three doses of HBV vaccine and again all of our participants were reevaluated in 2005. Hepatitis B surface antigen (HBsAg), antihepatitis B surface antibody (anti-HBsAb), and antihepatitis B core antibody (anti-HBcAb) were checked in all participants and those with anti-HBcAb above 10 IU/l were excluded from the final evaluation.
No participant was positive for HBsAg in either 1989 or 2005. Protective levels of anti-HBsAb were absent in all participants in 1989, but present in 67 (80.7%) participants in 2005 (P<0.001). Anti-HBsAb titer after vaccination was significantly higher in female participants than in male participants (P=0.01). Mean anti-HBsAb titer was 640+/-411.7 IU/l (range: 2-1000 IU/l) and the lowest protective titer was 12 IU/l.
According to our results, 80.7% of our participants had a protective titer of anti-HBsAb 16 years after vaccination. Although all anti-HBc positive participants were free of clinical hepatitis and were negative for HBsAg, hepatitis B vaccination was proved to be highly effective in preventing clinically significant infection and chronic carrier status up to 16 years after the primary vaccination. Hence, HBV revaccination may not be mandatory in healthcare workers, according to their sufficient long-term level of anti-HBsAb.
本研究旨在评估伊朗德黑兰石油公司医院医护人员接种乙肝病毒（HBV）疫苗16年的效果。
1989年，200名医护人员参与了本研究。检测了所有HBV标志物，HBV标志物阳性、抗丙型肝炎病毒或抗HIV阳性者被排除在研究之外。其余参与者接种了三剂HBV疫苗，2005年对所有参与者再次进行了评估。检测了所有参与者的乙肝表面抗原（HBsAg）、抗乙肝表面抗体（抗-HBsAb）和抗乙肝核心抗体（抗-HBcAb），抗-HBcAb高于10 IU/l者被排除在最终评估之外。
1989年和2005年，均无参与者HBsAg呈阳性。1989年所有参与者均无抗-HBsAb的保护水平，但2005年67名（80.7%）参与者有该保护水平（P<0.001）。接种疫苗后，女性参与者的抗-HBsAb滴度显著高于男性参与者（P=0.01）。抗-HBsAb平均滴度为640±411.7 IU/l（范围：2-1000 IU/l），最低保护滴度为12 IU/l。
根据我们的研究结果，80.7%的参与者在接种疫苗16年后有抗-HBsAb的保护滴度。尽管所有抗-HBc阳性参与者均无临床肝炎且HBsAg为阴性，但事实证明，乙肝疫苗接种在预防初次接种后长达16年的临床显著感染和慢性携带者状态方面非常有效。因此，根据医护人员抗-HBsAb的长期充足水平，可能无需强制进行HBV再接种。
